Yan Ning, Liu Cong, Tian Fang, Wang Ling, Wang Yimin, Yang Zhaoying, Jiao Yan, He Miao
Department of Breast Surgery, China-Japan Union Hospital of Jilin University, Changchun, Jilin 130033, China.
Department of Obstetrics and Gynecology, The Second Hospital of Jilin University, Changchun, Jilin 130022, China.
Int J Genomics. 2021 Feb 3;2021:4301802. doi: 10.1155/2021/4301802. eCollection 2021.
ZNF385B, a zinc finger protein, has been known as a potential biomarker in some neurological and hematological studies recently. Although numerous studies have demonstrated the potential function of zinc finger proteins in tumor progression, the effects of ZNF385B in breast cancer (BC) are less studied.
The Oncomine database and "ESurv" tool were used to explore the differential expression of ZNF385B in pan-cancer. Furthermore, data of patients with BC were downloaded from The Cancer Genome Atlas (TCGA). The receiver operating characteristic (ROC) curve of ZNF385B expression was established to explore the diagnostic value of ZNF385B and to obtain the cut-off value of high or low ZNF385B expression in BC. The chi-square test as well as Fisher exact test was used for identification of the relationships between clinical features and ZNF385B expression. Furthermore, the effects of ZNF385B on BC patients' survival were evaluated by the Kaplan-Meier and Cox regression. Data from the Gene Expression Omnibus (GEO) database were employed to validate the results of TCGA. Protein expression of ZNF385B in BC patient specimens was detected by immunohistochemistry (IHC) staining.
ZNF385B expression was downregulated in most types of cancer including BC. Low ZNF385B expression was related with survival status, overall survival (OS), and recurrence of BC. ZNF385B had modest diagnostic value, which is indicated by the area under the ROC curve (AUC = 0.671). Patients with lower ZNF385B expression had shorter OS and RFS (relapse-free survival). It had been demonstrated that low ZNF385B expression represented independent prognostic value for OS and RFS by multivariate survival analysis. The similar results were verified by datasets from the GEO database as well. The protein expression of ZNF385B was decreased in patients' samples compared with adjacent tissues by IHC.
Low ZNF385B expression was an independent predictor for worse prognosis of BC patients.
锌指蛋白ZNF385B最近在一些神经学和血液学研究中被认为是一种潜在的生物标志物。尽管众多研究已经证明锌指蛋白在肿瘤进展中的潜在功能，但ZNF385B在乳腺癌（BC）中的作用研究较少。
使用Oncomine数据库和“ESurv”工具探索ZNF385B在泛癌中的差异表达。此外，从癌症基因组图谱（TCGA）下载BC患者的数据。建立ZNF385B表达的受试者工作特征（ROC）曲线，以探索ZNF385B的诊断价值，并获得BC中ZNF385B高表达或低表达的临界值。使用卡方检验以及Fisher精确检验来确定临床特征与ZNF385B表达之间的关系。此外，通过Kaplan-Meier和Cox回归评估ZNF385B对BC患者生存的影响。使用来自基因表达综合数据库（GEO）的数据来验证TCGA的结果。通过免疫组织化学（IHC）染色检测BC患者标本中ZNF385B的蛋白表达。
ZNF385B表达在包括BC在内的大多数癌症类型中下调。低ZNF385B表达与BC的生存状态、总生存期（OS）和复发相关。ZNF385B具有中等诊断价值，ROC曲线下面积（AUC = 0.671）表明了这一点。ZNF385B表达较低的患者OS和无复发生存期（RFS）较短。多因素生存分析表明，低ZNF385B表达代表了OS和RFS的独立预后价值。来自GEO数据库的数据集也验证了类似结果。通过IHC检测，与相邻组织相比，患者样本中ZNF385B的蛋白表达降低。
低ZNF385B表达是BC患者预后较差的独立预测因素。
